320 related articles for article (PubMed ID: 27131639)
21. Discovery of N-aryl-N'-pyrimidin-4-yl ureas as irreversible L858R/T790M mutant selective epidermal growth factor receptor inhibitors.
Zhou F; Zhang L; Jin Y; Liu W; Cheng P; He X; Xie J; Shen S; Lei J; Ji H; Hu Y; Liu Y; Cui Y; Lv Q; Lan J
Bioorg Med Chem Lett; 2018 Apr; 28(7):1257-1261. PubMed ID: 29534926
[TBL] [Abstract][Full Text] [Related]
22. Noncovalent EGFR T790M/L858R inhibitors based on diphenylpyrimidine scaffold: Design, synthesis, and bioactivity evaluation for the treatment of NSCLC.
Chen L; Zhang Y; Tian L; Wang C; Deng T; Zheng X; Wang T; Li Z; Tang Z; Meng Q; Sun H; Li L; Ma X; Xu Y
Eur J Med Chem; 2021 Nov; 223():113626. PubMed ID: 34218082
[TBL] [Abstract][Full Text] [Related]
23. Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer.
Song Z; Ge Y; Wang C; Huang S; Shu X; Liu K; Zhou Y; Ma X
J Med Chem; 2016 Jul; 59(14):6580-94. PubMed ID: 26882288
[TBL] [Abstract][Full Text] [Related]
24. Discovery of pteridin-7(8H)-one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) kinase T790M/L858R mutant.
Zhou W; Liu X; Tu Z; Zhang L; Ku X; Bai F; Zhao Z; Xu Y; Ding K; Li H
J Med Chem; 2013 Oct; 56(20):7821-37. PubMed ID: 24053674
[TBL] [Abstract][Full Text] [Related]
25. Design, Synthesis, and Biological Evaluation of Pyrimido[4,5- d]pyrimidine-2,4(1 H,3 H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.
Hao Y; Lyu J; Qu R; Tong Y; Sun D; Feng F; Tong L; Yang T; Zhao Z; Zhu L; Ding J; Xu Y; Xie H; Li H
J Med Chem; 2018 Jul; 61(13):5609-5622. PubMed ID: 29906114
[TBL] [Abstract][Full Text] [Related]
26. Rational design and synthesis of 2,4-dichloro-6-methyl pyrimidine derivatives as potential selective EGFR
Duan L; Chu C; Huang X; Yao H; Wen J; Chen R; Wang C; Tu Y; Lv Q; Pan Q; Xu S
Arch Pharm (Weinheim); 2024 May; 357(5):e2300736. PubMed ID: 38381049
[TBL] [Abstract][Full Text] [Related]
27. Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation.
Sos ML; Rode HB; Heynck S; Peifer M; Fischer F; Klüter S; Pawar VG; Reuter C; Heuckmann JM; Weiss J; Ruddigkeit L; Rabiller M; Koker M; Simard JR; Getlik M; Yuza Y; Chen TH; Greulich H; Thomas RK; Rauh D
Cancer Res; 2010 Feb; 70(3):868-74. PubMed ID: 20103621
[TBL] [Abstract][Full Text] [Related]
28. C-2 (E)-4-(Styryl)aniline substituted diphenylpyrimidine derivatives (Sty-DPPYs) as specific kinase inhibitors targeting clinical resistance related EGFR
Song A; Zhang J; Ge Y; Wang C; Meng Q; Tang Z; Peng J; Liu K; Li Y; Ma X
Bioorg Med Chem; 2017 May; 25(10):2724-2729. PubMed ID: 28385595
[TBL] [Abstract][Full Text] [Related]
29. In-silico evidences for binding of Glucokinase activators to EGFR C797S to overcome EGFR resistance obstacle with mutant-selective allosteric inhibition.
Patel H; Pawara R; Surana S
Comput Biol Chem; 2018 Jun; 74():167-189. PubMed ID: 29627693
[TBL] [Abstract][Full Text] [Related]
30. Insight into Discovery of Next Generation Reversible TMLR Inhibitors Targeting EGFR Activating and Drug Resistant T790M Mutants.
Agarwal SM; Pal D; Gupta M; Saini R
Curr Cancer Drug Targets; 2017; 17(7):617-636. PubMed ID: 28359250
[TBL] [Abstract][Full Text] [Related]
31. Hybrids of Quinoline and Anilinopyrimidine: Novel EGFRT790M Inhibitors with Antiproliferative Activity against Non-Small Cell Lung Cancer Cell Lines.
Han C; Ren J; Su F; Hu X; Li M; Wang Z; Wu L
Anticancer Agents Med Chem; 2020; 20(6):724-733. PubMed ID: 32116203
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and biological evaluation of irreversible EGFR tyrosine kinase inhibitors containing pyrido[3,4-d]pyrimidine scaffold.
Zhang H; Wang J; Zhao HY; Yang XY; Lei H; Xin M; Cao YX; Zhang SQ
Bioorg Med Chem; 2018 Jul; 26(12):3619-3633. PubMed ID: 29853340
[TBL] [Abstract][Full Text] [Related]
34. A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFR
Yu L; Huang M; Xu T; Tong L; Yan XE; Zhang Z; Xu Y; Yun C; Xie H; Ding K; Lu X
Eur J Med Chem; 2017 Jan; 126():1107-1117. PubMed ID: 28033579
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and biological evaluation of azole-diphenylpyrimidine derivatives (AzDPPYs) as potent T790M mutant form of epidermal growth factor receptor inhibitors.
Song Z; Jin Y; Ge Y; Wang C; Zhang J; Tang Z; Peng J; Liu K; Li Y; Ma X
Bioorg Med Chem; 2016 Nov; 24(21):5505-5512. PubMed ID: 27634676
[TBL] [Abstract][Full Text] [Related]
36. Novel 4-anilinoquinazoline derivatives featuring an 1-adamantyl moiety as potent EGFR inhibitors with enhanced activity against NSCLC cell lines.
Yu H; Li Y; Ge Y; Song Z; Wang C; Huang S; Jin Y; Han X; Zhen Y; Liu K; Zhou Y; Ma X
Eur J Med Chem; 2016 Mar; 110():195-203. PubMed ID: 26829280
[TBL] [Abstract][Full Text] [Related]
37. Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
Engel J; Smith S; Lategahn J; Tumbrink HL; Goebel L; Becker C; Hennes E; Keul M; Unger A; Müller H; Baumann M; Schultz-Fademrecht C; Günther G; Hengstler JG; Rauh D
J Med Chem; 2017 Sep; 60(18):7725-7744. PubMed ID: 28853575
[TBL] [Abstract][Full Text] [Related]
38. Transtinib, a potent tyrosine kinase inhibitor inhibits L858R/T790M mutant NSCLC cell lines and xenografts.
Hu P; Han DX; Ruan RS; Zheng LM; Chou SH; Tzeng CM
Oncotarget; 2016 Jun; 7(24):35741-35752. PubMed ID: 26848869
[TBL] [Abstract][Full Text] [Related]
39. Novel 4-arylaminoquinazoline derivatives with (E)-propen-1-yl moiety as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.
Chen L; Zhang Y; Liu J; Wang W; Li X; Zhao L; Wang W; Li B
Eur J Med Chem; 2017 Sep; 138():689-697. PubMed ID: 28711703
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis and biological evaluation of novel 2,4-diaryl pyrimidine derivatives as selective EGFR
Li J; An B; Song X; Zhang Q; Chen C; Wei S; Fan R; Li X; Zou Y
Eur J Med Chem; 2021 Feb; 212():113019. PubMed ID: 33429247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
